ClinicalTrials.gg
Active, not recruitingNCT04963296ALLEGORYUpdated Nov 12, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

A Phase 3 interventional study of Obinutuzumab and Placebo in Systemic Lupus Erythematosus, sponsored by Hoffmann-La Roche. Active, not recruiting at 63 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.

Enrollment
2nd of 14
303 · median 65
Started
2021
the only one that year
Phase 3
4 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 4 in phase 3, and was the 9th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria >=12 weeks prior to screening
  • Anti-nuclear antibody (ANA) >=1:80, or anti-dsDNA and/or anti-Sm antibodies above the (ULN), as determined by the central laboratory at screening
  • Low C3 or low C4 or low CH50 complement as determined by the central laboratory at screening
  • High disease activity at screening, based on; BILAG-2004 (Category A disease in >=1 organ system and/or Category B disease in >=2 organ systems), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (score >=8) and Physician's Global Assessment (PGA) (score >=1.0 on a 0 to 3 visual analogue scale [VAS])
  • High disease activity on Day 1, based on; SLEDAI-2K (score >=8) and PGA (score >=1.0 on a 0 to 3 VAS)
  • Current receipt of >=1 of the following classes of standard therapies for the treatment of SLE at stable doses: oral (OCS), antimalarials, conventional
  • Other inclusion criteria may apply
  • The Medical Monitor may be consulted if there are any questions related to eligibility criteria

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Presence of significant lupus-associated renal disease and/or renal impairment
  • Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
  • Known active infection of any kind or recent major episode of infection
  • Intolerance or to study therapies
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    Obinutuzumab

    Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.

    Drug: Obinutuzumab · Drug: Acetaminophen/Paracetamol · Drug: Diphenhydramine hydrochloride · Drug: Methylprednisolone

  • Placebo comparator
    Placebo

    Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.

    Drug: Placebo · Drug: Acetaminophen/Paracetamol · Drug: Diphenhydramine hydrochloride · Drug: Methylprednisolone

Interventions

  • Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.

    Also known as: Gazyva, GA101, RO5072759

  • DrugPlacebo

    Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.

  • DrugAcetaminophen/Paracetamol

    Drug page: Acetaminophen

    Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

  • Diphenhydramine 50 mg will be administered as premedication prior to infusions.

  • Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52

    Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by \>=1 new British Isles Lupus Assessment Group (BILAG) A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52

    Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 52

  2. Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52

    Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

    Time frame: From Week 40 through Week 52

  3. Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52

    Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: From Week 40 Through Week 52

  4. Percentage of Participants With SRI(6) Response at Week 52

    Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 52

  5. Time to BILAG Flare Over 52 Weeks

    BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare.

    Time frame: At Week 52

  6. Percentage of Participants Who Achieved SRI(4) at Week 24

    Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 24

  7. Percentage of Participants Who Achieved Clinical SRI(4) at Week 52

    Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 52

  8. Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids

    Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of \>=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS; 4) Prednisone \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 52

  9. Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52

    LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K \<=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS \<=1; 4) Current prednisone dose \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

    Time frame: At Week 52

  10. Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52

    DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS \<0.5; 3) Current prednisone dose \<=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders.

    Time frame: At Week 52

  11. Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52

    The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model.

    Time frame: Baseline, Weeks 24 and 52

  12. Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

    Time frame: Baseline, Weeks 24 and 52

  13. Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

    Time frame: Baseline, Weeks 24 and 52

  14. Change in Active Joint Count From Baseline to Weeks 24 and 52

    Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

    Time frame: Baseline, Weeks 24 and 52

  15. Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline

    Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

    Time frame: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52

  16. Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit

    CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

    Time frame: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52

  17. Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52

    Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

    Time frame: From Week 40 through Week 52

  18. Cumulative Corticosteroid Use Through Week 52

    Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant.

    Time frame: Up to Week 52

  19. Annualized Flare Rate Through Week 52

    BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period).

    Time frame: Up to Week 52

  20. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

    Time frame: Up to Week 52

  21. Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia

    AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade \>=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions.

    Time frame: Up to Week 52

  22. Maximum Serum Concentration (Cmax) of Obinutuzumab

    Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here.

    Time frame: From Weeks 0-24 and Weeks 24-52

  23. Trough Concentration (Ctrough) of Obinutuzumab

    Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals.

    Time frame: From Weeks 0-24 and Weeks 24-52

  24. Area Under the Concentration-time Curve (AUC) of Obinutuzumab

    AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks.

    Time frame: Week 0-52

  25. Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab

    Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

    Time frame: Up to Week 52

07

Results

Posted Nov 12, 2026

Participant flow

A total of 303 participants with active, autoantibody-positive systemic lupus erythematosus (SLE) treated with standard-of-care therapy took part in the study at 64 investigative sites across 14 countries. Participants were randomized in a 1:1 ratio to receive either obinutuzumab or placebo in the blinded treatment period.

Participant flow — Overall Study
MilestoneObinutuzumabPlacebo
Started151152
Safety-evaluable set151151
Completed144136
Not completed716
Withdrew: Adverse event12
Withdrew: Death13
Withdrew: Lack of efficacy03
Withdrew: Lost to follow-up02
Withdrew: Physician decision01
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject54

Outcome measures

PrimaryPercentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by \>=1 new British Isles Lupus Assessment Group (BILAG) A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 5276.7 (69.80 to 83.53)53.5 (45.33 to 61.60)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Adjusted difference: 23.1 · 95% CI 12.52 to 33.63
SecondaryPercentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52

Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 5262.0 (54.23 to 69.82)40.1 (32.12 to 48.07)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0002 · Adjusted difference: 21.9 · 95% CI 10.81 to 32.90
SecondaryPercentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52

Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

Time frame:
From Week 40 through Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 5280.0 (71.50 to 88.50)54.1 (43.52 to 64.71)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0003 · Adjusted difference: 26.08 · 95% CI 12.65 to 39.51
SecondaryPercentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
From Week 40 Through Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 5272.0 (64.60 to 79.31)46.4 (38.29 to 54.57)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Adjusted difference: 25.4 · 95% CI 14.56 to 36.24
SecondaryPercentage of Participants With SRI(6) Response at Week 52

Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With SRI(6) Response at Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants With SRI(6) Response at Week 5268.9 (61.44 to 76.45)38.9 (30.98 to 46.85)
Statistical analysis
  • Obinutuzumab vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Adjusted difference: 30.0 · 95% CI 19.17 to 40.74
SecondaryTime to BILAG Flare Over 52 Weeks

BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare.

Time frame:
At Week 52
Reported as:
Median · weeks
Time to BILAG Flare Over 52 Weeks
weeksObinutuzumabPlacebo
Time to BILAG Flare Over 52 WeeksNA (NA to NA)52.3 (35.1 to NA)
Statistical analysis
  • Obinutuzumab vs Placebo · Log Rank · p = 0.0023 · Hazard ratio (hr): 0.58 · 95% CI 0.40 to 0.82
SecondaryPercentage of Participants Who Achieved SRI(4) at Week 24

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved SRI(4) at Week 24
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved SRI(4) at Week 2473.555.9
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 17.56 · 95% CI 7.08 to 28.04
SecondaryPercentage of Participants Who Achieved Clinical SRI(4) at Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical SRI(4) at Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved Clinical SRI(4) at Week 5274.850.0
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 24.71 · 95% CI 14.26 to 35.17
SecondaryPercentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids

Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of \>=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS; 4) Prednisone \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids74.247.4
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 26.72 · 95% CI 16.25 to 37.20
SecondaryPercentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52

LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K \<=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS \<=1; 4) Current prednisone dose \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 5257.625.0
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 32.61 · 95% CI 22.25 to 42.98
SecondaryPercentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52

DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS \<0.5; 3) Current prednisone dose \<=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 5233.813.8
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 19.86 · 95% CI 10.55 to 29.17
SecondaryChange in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52

The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · score on a scale
Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52
score on a scaleObinutuzumabPlacebo
Change at Week 246.82 ± 0.8285.64 ± 0.842
Change at Week 528.44 ± 0.7775.66 ± 0.805
Statistical analysis
  • Obinutuzumab vs Placebo · Difference in adjusted means: 1.18 · 95% CI -1.08 to 3.45
  • Obinutuzumab vs Placebo · Difference in adjusted means: 2.78 · 95% CI 0.62 to 4.94
SecondaryChange in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · score on a scale
Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52
score on a scaleObinutuzumabPlacebo
Change at Week 247.06 ± 0.7864.46 ± 0.790
Change at Week 528.11 ± 0.7575.60 ± 0.760
Statistical analysis
  • Obinutuzumab vs Placebo · Difference in adjusted means: 2.60 · 95% CI 0.46 to 4.74
  • Obinutuzumab vs Placebo · Difference in adjusted means: 2.50 · 95% CI 0.44 to 4.56
SecondaryChange in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · score on a scale
Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52
score on a scaleObinutuzumabPlacebo
Change at Week 245.98 ± 0.6404.21 ± 0.641
Change at Week 526.97 ± 0.6595.46 ± 0.661
Statistical analysis
  • Obinutuzumab vs Placebo · Difference in adjusted means: 1.77 · 95% CI 0.03 to 3.51
  • Obinutuzumab vs Placebo · Difference in adjusted means: 1.51 · 95% CI -0.28 to 3.30
SecondaryChange in Active Joint Count From Baseline to Weeks 24 and 52

Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · active joints
Change in Active Joint Count From Baseline to Weeks 24 and 52
active jointsObinutuzumabPlacebo
Change at Week 24-5.70 ± 0.347-5.44 ± 0.348
Change at Week 52-6.42 ± 0.319-5.69 ± 0.319
Statistical analysis
  • Obinutuzumab vs Placebo · Difference in adjusted means: -0.26 · 95% CI -1.21 to 0.68
  • Obinutuzumab vs Placebo · Difference in adjusted means: -0.73 · 95% CI -1.60 to 0.14
SecondaryPercentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline

Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

Time frame:
At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline
percentage of participantsObinutuzumabPlacebo
Week 2480.572.6
Week 2885.274.2
Week 3283.672.6
Week 3684.474.2
Week 4083.673.4
Week 4482.869.4
Week 4883.668.5
Week 5280.566.1
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 8.77 · 95% CI -1.66 to 19.20
  • Obinutuzumab vs Placebo · Adjusted difference: 11.56 · 95% CI 1.64 to 21.47
  • Obinutuzumab vs Placebo · Adjusted difference: 11.32 · 95% CI 1.15 to 21.48
  • Obinutuzumab vs Placebo · Adjusted difference: 10.53 · 95% CI 0.55 to 20.52
  • Obinutuzumab vs Placebo · Adjusted difference: 10.45 · 95% CI 0.33 to 20.56
  • Obinutuzumab vs Placebo · Adjusted difference: 13.94 · 95% CI 3.51 to 24.37
  • Obinutuzumab vs Placebo · Adjusted difference: 15.43 · 95% CI 5.03 to 25.83
  • Obinutuzumab vs Placebo · Adjusted difference: 14.75 · 95% CI 3.98 to 25.52
SecondaryPercentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit

CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

Time frame:
At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit
percentage of participantsObinutuzumabPlacebo
Week 2467.958.0
Week 2873.660.0
Week 3273.658.0
Week 3671.760.0
Week 4073.660.0
Week 4471.756.0
Week 4871.756.0
Week 5266.058.0
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 11.20 · 95% CI -7.18 to 29.58
  • Obinutuzumab vs Placebo · Adjusted difference: 14.09 · 95% CI -3.94 to 32.11
  • Obinutuzumab vs Placebo · Adjusted difference: 16.53 · 95% CI -1.49 to 34.55
  • Obinutuzumab vs Placebo · Adjusted difference: 12.50 · 95% CI -5.63 to 30.64
  • Obinutuzumab vs Placebo · Adjusted difference: 15.79 · 95% CI -2.09 to 33.66
  • Obinutuzumab vs Placebo · Adjusted difference: 17.10 · 95% CI -1.03 to 35.24
  • Obinutuzumab vs Placebo · Adjusted difference: 17.77 · 95% CI -0.32 to 35.86
  • Obinutuzumab vs Placebo · Adjusted difference: 9.25 · 95% CI -9.18 to 27.68
SecondaryPercentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52

Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

Time frame:
From Week 40 through Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52
percentage of participantsObinutuzumabPlacebo
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 5272.9 (63.50 to 82.39)49.4 (38.78 to 60.04)
Statistical analysis
  • Obinutuzumab vs Placebo · Adjusted difference: 23.72 · 95% CI 9.74 to 37.69
SecondaryCumulative Corticosteroid Use Through Week 52

Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant.

Time frame:
Up to Week 52
Reported as:
Mean · mg
Cumulative Corticosteroid Use Through Week 52
mgObinutuzumabPlacebo
Cumulative Corticosteroid Use Through Week 522422.2 ± 1421.02739.0 ± 1495.4
SecondaryAnnualized Flare Rate Through Week 52

BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period).

Time frame:
Up to Week 52
Reported as:
Number · flares per participant-year
Annualized Flare Rate Through Week 52
flares per participant-yearObinutuzumabPlacebo
Annualized Flare Rate Through Week 520.38 (0.28 to 0.51)0.62 (0.48 to 0.81)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsObinutuzumabPlacebo
Number of Participants With Adverse Events (AEs)134123
SecondaryNumber of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia

AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade \>=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia
ParticipantsObinutuzumabPlacebo
IRRs185
Grade 3 or Higher Infections117
Drug-related Neutropenia73
Drug-related Thrombocytopenia00
Gastrointestinal Perforations01
Hy's Law01
Worsening of Pre-existing Cardiac Conditions00
Any Hepatitis B Reactivation or PML00
SecondaryMaximum Serum Concentration (Cmax) of Obinutuzumab

Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here.

Time frame:
From Weeks 0-24 and Weeks 24-52
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Maximum Serum Concentration (Cmax) of Obinutuzumab
micrograms per milliliter (μg/mL)Obinutuzumab
Week 0-24557 ± 28.3
Week 24-52603 ± 26.5
SecondaryTrough Concentration (Ctrough) of Obinutuzumab

Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals.

Time frame:
From Weeks 0-24 and Weeks 24-52
Reported as:
Geometric mean · μg/mL
Trough Concentration (Ctrough) of Obinutuzumab
μg/mLObinutuzumab
Week 0-241.74 ± 131
Week 24-521.72 ± 183
SecondaryArea Under the Concentration-time Curve (AUC) of Obinutuzumab

AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks.

Time frame:
Week 0-52
Reported as:
Geometric mean · μg/mL*day
Area Under the Concentration-time Curve (AUC) of Obinutuzumab
μg/mL*dayObinutuzumab
Area Under the Concentration-time Curve (AUC) of Obinutuzumab51600 ± 27.3
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab

Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab
ParticipantsObinutuzumab
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab5

Adverse events

Collected over All-cause Mortality: Up to primary clinical cut-off (approximately 46 months) SAEs and Other AEs: Up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab 1000mg1/151 (0.7%)24/151 (15.9%)92/151 (60.9%)
Placebo5/151 (3.3%)18/151 (11.9%)76/151 (50.3%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventObinutuzumab 1000mgPlacebo
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/1516/151
PneumoniaInfections and infestations3/1513/151
Chest painGeneral disorders0/1512/151
GastroenteritisInfections and infestations0/1512/151
SepsisInfections and infestations1/1512/151
Upper respiratory tract infectionInfections and infestations2/1510/151
Urinary tract infectionInfections and infestations2/1510/151
Infusion related reactionInjury, poisoning and procedural complications2/1510/151
AnaemiaBlood and lymphatic system disorders1/1511/151
NeutropeniaBlood and lymphatic system disorders1/1511/151
Most frequent other events
Showing 10 of 11
Most frequent other events
EventObinutuzumab 1000mgPlacebo
Upper respiratory tract infectionInfections and infestations27/15119/151
Urinary tract infectionInfections and infestations24/15117/151
Infusion related reactionInjury, poisoning and procedural complications14/1515/151
DiarrhoeaGastrointestinal disorders7/15113/151
NasopharyngitisInfections and infestations13/1517/151
HeadacheNervous system disorders11/15113/151
AnaemiaBlood and lymphatic system disorders5/15111/151
BronchitisInfections and infestations9/1518/151
COVID-19Infections and infestations9/1516/151
PharyngitisInfections and infestations8/1516/151

Baseline characteristics

Efficacy-evaluable (EE) set included all randomized participants, with participants grouped according to assigned treatment.

Age, Continuous
Age, Continuous(years)ObinutuzumabPlaceboTotal
Mean41.1 ± 12.341.4 ± 12.641.2 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)ObinutuzumabPlaceboTotal
Female139135274
Male121729
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ObinutuzumabPlaceboTotal
Hispanic or Latino7586161
Not Hispanic or Latino7365138
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ObinutuzumabPlaceboTotal
American Indian or Alaska Native444286
Asian426
Native Hawaiian or Other Pacific Islander011
Black or African American222547
White6462126
More than one race71118
Unknown or Not Reported10919
08

Study locations

63 sites
09

References and documents

Publications

  • Furie RA, Dall'Era M, Vital EM, Garg JP, Irazoque Palazuelos F, Zuta Santillan AE, Ravelo-Hernandez J, Santiago MB, Zazueta Montiel B, Botha S, Leszczynski P, de Souza VA, Sicsik SA, Bellatin L, Naidoo A, Amoura Z, D'Agostino MA, Kumar S, Workeneh B, Rae J, Mao HA, Erblang F, Meier O, Maller JC, Askanase AD; ALLEGORY Trial Investigators. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2026 Jul 16;395(3):243-254. doi: 10.1056/NEJMoa2516150. Epub 2026 Mar 6. PubMed 41789864 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Sep 2025, 46 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2021
First posted
Jul 15, 2021
StartActual
Oct 26, 2021
Primary completionActual
Sep 15, 2025
CompletionEst.
Mar 13, 2028
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Sites
1 site added, 2 sites removed
Show site
  • Clinical Trials Network Helderberg · Somerset West, South Africa
Show 2 removed
  • Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI) · Culiacán, Mexico
  • Winelands Medical Research · Cape Town, South Africa
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of Participants who Achieve Systemic Lupus ErythematosusWho Achieved SLE Responder Index (SRI[4]SRI4) at Week 52Time frame: Week 52 → At Week 52
Nov 12, 2026
Documents
Secondary outcomes
19 edited, 6 added, 5 removed, 1 more
What changed in the outcomes
  • EditedPercentage of Participants who Achieve SRIWho Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (6BICLA) at Week 52Time frame: Week 52 → At Week 52
  • EditedTime to First BILAG Flare overOver 52 WeeksTime frame: From baseline to Week 52 → At Week 52
  • EditedPercentage of Participants who Achieve aWho Achieved Sustained SRI(4) Response From Week 40 Through Week 52Time frame: From Week 40 to Week 52 → From Week 40 Through Week 52
  • EditedPercentage of Participants who Achieve British Isles Lupus Assessment Group-based Composite Lupus Assessment Who Achieved Clinical SRI(BICLA4) at Week 52Time frame: Week 52 → At Week 52
  • EditedPercentage of Participants who AchieveWith SRI(86) Response at Week 52Time frame: Week 52 → At Week 52
  • EditedPercentage of Participants who AchieveWho Achieved SRI(4) at Week 24Time frame: Week 24 → At Week 24
  • EditedPercentage of Participants who Achieve ClinicalWho Achieved SRI(4) at Week 52 on Low-dose of CorticosteroidsTime frame: Week 52 → At Week 52
  • EditedPercentage of Participants who Achieve SRIWho Achieved Lupus Low Disease Activity State (4LLDAS) at Week 52 on Low-dose CorticosteroidsTime frame: Week 52 → At Week 52
  • EditedPercentage of Participants who Achieve Lupus Low Disease Activity StateWho Achieved Definition of Remission in SLE (LLDASDORIS) at Week 52Time frame: Week 52 → At Week 52
  • EditedChange in Functional Assessment of Chronic Illness Therapy-Fatiguefatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52Time frame: From baseline to Week 24 and from baseline to Week 52 → Baseline, Weeks 24 and 52
  • EditedChange in 36-Item Short Form Survey, Version 2 (SF-36 v2V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52Time frame: From baseline to Week 24 and from baseline to Week 52 → Baseline, Weeks 24 and 52
  • EditedChange in SF-36 v2V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52Time frame: From baseline to Week 24 and from baseline to Week 52 → Baseline, Weeks 24 and 52
  • EditedPercentage of Participants who AchieveWho Achieved a >= 50% Reduction in Active Joint Counts (Swollen plus Tender) at Each Study Visit, Among Participants With >=4 Active Joints at BaselineTime frame: From baseline to Week 52 → At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
  • EditedPercentage of Participants who AchieveWho Achieved a >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at eachEach Study Visit, among Participants with CLASI Total Activity Score >=10 at BaselineTime frame: From baseline to Week 52 → At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
  • EditedAnnualized flare rate throughCumulative Corticosteroid Use Through Week 52Time frame: At Week 52 → Up to Week 52
  • EditedPercentageNumber of Participants withWith Adverse Events (AEs)Time frame: From baseline to approximately 6 years → Up to Week 52
  • EditedPercentageNumber of Participants withWith Adverse Events of Special InterestInterests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and ThrombocytopeniaTime frame: From baseline to approximately 6 years → Up to Week 52
  • EditedMaximum Serum Concentration (Cmax) of ObinutuzumabTime frame: Double blind period: At Weeks 2, 4, 12, 24, 26, 36, 52 and at early study discontinuation visit; Open label period: At Weeks 54, 56, 58, 66, 78, 90, 104 and at early study discontinuation visit → From Weeks 0-24 and Weeks 24-52
  • EditedPercentageNumber of Participants withWith Anti-drug Antibodies (ADAs) at Baselineto ObinutuzumabTime frame: Baseline → Up to Week 52
  • AddedPercentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52Time frame: From Week 40 through Week 52
  • AddedChange in Active Joint Count From Baseline to Weeks 24 and 52Time frame: Baseline, Weeks 24 and 52
  • AddedPercentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52Time frame: From Week 40 through Week 52
  • AddedAnnualized Flare Rate Through Week 52Time frame: Up to Week 52
  • AddedTrough Concentration (Ctrough) of ObinutuzumabTime frame: From Weeks 0-24 and Weeks 24-52
  • AddedArea Under the Concentration-time Curve (AUC) of ObinutuzumabTime frame: Week 0-52
  • RemovedPercentage of Participants Entering the Study on Prednisone >= 10 mg/day (or equivalent) who Achieve Sustained Corticosteroid ControlTime frame: From Week 40 to Week 52
  • RemovedPercentage of Participants who Achieve Definition of Remission in SLE (DORIS) at Week 52Time frame: Week 52
  • RemovedChange in Active Joint Count (Swollen plus Tender)Time frame: From baseline to Week 24 and from baseline to Week 52
  • RemovedPercentage of Participants who Achieve Sustained Corticosteroid ControlTime frame: From Week 40 through Week 52
  • RemovedCumulative Corticosteroid use (in Equivalent Milligrams of Prednisone)Time frame: From baseline to Week 52
  • …and 1 more, on the record history on ClinicalTrials.gov ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    1 site added, 2 sites removed
    Show site
    • Clinical Trials Network Helderberg · Somerset West, South Africa
    Show 2 removed
    • Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI) · Culiacán, Mexico
    • Winelands Medical Research · Cape Town, South Africa
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of Participants who Achieve Systemic Lupus ErythematosusWho Achieved SLE Responder Index (SRI[4]SRI4) at Week 52Time frame: Week 52 → At Week 52
    Secondary outcomes 19 edited, 6 added, 5 removed, 1 more
    What changed in the outcomes
    • EditedPercentage of Participants who Achieve SRIWho Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (6BICLA) at Week 52Time frame: Week 52 → At Week 52
    • EditedTime to First BILAG Flare overOver 52 WeeksTime frame: From baseline to Week 52 → At Week 52
    • EditedPercentage of Participants who Achieve aWho Achieved Sustained SRI(4) Response From Week 40 Through Week 52Time frame: From Week 40 to Week 52 → From Week 40 Through Week 52
    • EditedPercentage of Participants who Achieve British Isles Lupus Assessment Group-based Composite Lupus Assessment Who Achieved Clinical SRI(BICLA4) at Week 52Time frame: Week 52 → At Week 52
    • EditedPercentage of Participants who AchieveWith SRI(86) Response at Week 52Time frame: Week 52 → At Week 52
    • EditedPercentage of Participants who AchieveWho Achieved SRI(4) at Week 24Time frame: Week 24 → At Week 24
    • EditedPercentage of Participants who Achieve ClinicalWho Achieved SRI(4) at Week 52 on Low-dose of CorticosteroidsTime frame: Week 52 → At Week 52
    • EditedPercentage of Participants who Achieve SRIWho Achieved Lupus Low Disease Activity State (4LLDAS) at Week 52 on Low-dose CorticosteroidsTime frame: Week 52 → At Week 52
    • EditedPercentage of Participants who Achieve Lupus Low Disease Activity StateWho Achieved Definition of Remission in SLE (LLDASDORIS) at Week 52Time frame: Week 52 → At Week 52
    • EditedChange in Functional Assessment of Chronic Illness Therapy-Fatiguefatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52Time frame: From baseline to Week 24 and from baseline to Week 52 → Baseline, Weeks 24 and 52
    • EditedChange in 36-Item Short Form Survey, Version 2 (SF-36 v2V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52Time frame: From baseline to Week 24 and from baseline to Week 52 → Baseline, Weeks 24 and 52
    • EditedChange in SF-36 v2V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52Time frame: From baseline to Week 24 and from baseline to Week 52 → Baseline, Weeks 24 and 52
    • EditedPercentage of Participants who AchieveWho Achieved a >= 50% Reduction in Active Joint Counts (Swollen plus Tender) at Each Study Visit, Among Participants With >=4 Active Joints at BaselineTime frame: From baseline to Week 52 → At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
    • EditedPercentage of Participants who AchieveWho Achieved a >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at eachEach Study Visit, among Participants with CLASI Total Activity Score >=10 at BaselineTime frame: From baseline to Week 52 → At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
    • EditedAnnualized flare rate throughCumulative Corticosteroid Use Through Week 52Time frame: At Week 52 → Up to Week 52
    • EditedPercentageNumber of Participants withWith Adverse Events (AEs)Time frame: From baseline to approximately 6 years → Up to Week 52
    • EditedPercentageNumber of Participants withWith Adverse Events of Special InterestInterests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and ThrombocytopeniaTime frame: From baseline to approximately 6 years → Up to Week 52
    • EditedMaximum Serum Concentration (Cmax) of ObinutuzumabTime frame: Double blind period: At Weeks 2, 4, 12, 24, 26, 36, 52 and at early study discontinuation visit; Open label period: At Weeks 54, 56, 58, 66, 78, 90, 104 and at early study discontinuation visit → From Weeks 0-24 and Weeks 24-52
    • EditedPercentageNumber of Participants withWith Anti-drug Antibodies (ADAs) at Baselineto ObinutuzumabTime frame: Baseline → Up to Week 52
    • AddedPercentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52Time frame: From Week 40 through Week 52
    • AddedChange in Active Joint Count From Baseline to Weeks 24 and 52Time frame: Baseline, Weeks 24 and 52
    • AddedPercentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52Time frame: From Week 40 through Week 52
    • AddedAnnualized Flare Rate Through Week 52Time frame: Up to Week 52
    • AddedTrough Concentration (Ctrough) of ObinutuzumabTime frame: From Weeks 0-24 and Weeks 24-52
    • AddedArea Under the Concentration-time Curve (AUC) of ObinutuzumabTime frame: Week 0-52
    • RemovedPercentage of Participants Entering the Study on Prednisone >= 10 mg/day (or equivalent) who Achieve Sustained Corticosteroid ControlTime frame: From Week 40 to Week 52
    • RemovedPercentage of Participants who Achieve Definition of Remission in SLE (DORIS) at Week 52Time frame: Week 52
    • RemovedChange in Active Joint Count (Swollen plus Tender)Time frame: From baseline to Week 24 and from baseline to Week 52
    • RemovedPercentage of Participants who Achieve Sustained Corticosteroid ControlTime frame: From Week 40 through Week 52
    • RemovedCumulative Corticosteroid use (in Equivalent Milligrams of Prednisone)Time frame: From baseline to Week 52
    • …and 1 more, on the record history on ClinicalTrials.gov ↗
    + 4 other changes: identifiers, verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04963296
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 15, 2021
Start date
Oct 26, 2021
Primary completion
Sep 15, 2025
Completion
Mar 13, 2028 (estimated)
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion